Therapeutics News and Research

RSS

Promedior's PRM-151 clinical data in idiopathic pulmonary fibrosis to be presented at ATS 2011

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, today announced that data from a clinical study of PRM-151 will be presented at the 2011 American Thoracic Society International Conference, being held May 13-18, 2011 in Denver, CO.

5 May 2011

The Miami Project, InVivo Therapeutics collaborate to develop novel spinal cord injury treatments

InVivo Therapeutics, a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries, and The University of Miami Miller School of Medicine's Miami Project to Cure Paralysis, the world's most comprehensive spinal cord injury research center, today announced a strategic research collaboration for the development of novel SCI treatments.

5 May 2011

ZIOPHARM reports net loss of $39.0 million for first quarter 2011

ZIOPHARM Oncology, Inc, an oncology small molecule and synthetic biology drug development company, today reported its financial results for the three months ended March 31, 2011, and provided an update on the Company's activities in the first quarter.

5 May 2011

Research experts to speak at brain tumor educational conference

Patients, families and caregivers are invited to attend an educational conference covering many aspects of brain tumors May 14 at Cedars-Sinai Medical Center.

5 May 2011

TGen licenses ONCO-101 cancer drug to Syracuse

The Translational Genomics Research Institute has licensed its first drug, a unique compound that targets cancer tumors by modifying the actions of proteins.

5 May 2011

Selexys begins patient enrollment in SelG1 Phase I study for sickle cell disease

Selexys Pharmaceuticals announced today that it has initiated enrollment in a Phase I clinical study of its lead compound, SelG1, a humanized anti-P-selectin antibody.

5 May 2011

Durata receives positive EMA Scientific Advice on dalbavancin clinical development plan

Durata Therapeutics today announced the Company has received positive Scientific Advice from the European Medicines Agency on the pivotal clinical development plan for dalbavancin, Durata's long-acting, intravenous lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections.

4 May 2011

Nile Therapeutics initiates cenderitide Phase I trial in heart failure

Nile Therapeutics, Inc., a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced dosing of the first patient in a Phase I clinical trial investigating the use of subcutaneous cenderitide.

3 May 2011

CTI to re-submit pixantrone NDA to FDA's Office of New Drugs for re-review

Cell Therapeutics, today announced that the Office of New Drugs of the U.S. Food and Drug Administration after carefully reviewing the materials CTI submitted in support of its appeal, the reviews of the New Drug Application for pixantrone prepared by the FDA staff, the transcript of the March 22, 2010 Oncology Drugs Advisory Committee meeting and consulting with the Center for Drug Evaluation and Research's Deputy Director of Clinical Science and the Office of Biostatistics, concluded that accelerated approval of pixantrone NDA 022481 may not necessarily be out of reach based on a single controlled clinical trial, provided two key matters can be satisfactorily resolved.

3 May 2011

Astex earns GBP5.9 M milestone payment from GSK for fragment-based screening platform

Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, announced that it has achieved multiple early milestones in its fragment-based drug discovery collaboration with GlaxoSmithKline which commenced in November 2009.

3 May 2011

JPO issues patent to Silence Therapeutics' RNAi technology

Silence Therapeutics plc announces the issuance of patent 4,705,370, titled "Further Novel Forms of Interfering RNA Molecules," by the Japanese Patent Office.

3 May 2011

Guided Therapeutics launches LuViva Advanced Cervical Scan

Guided Therapeutics, Inc., unveiled the new name and new industrial design for its non-invasive and painless test for the early detection of cervical precancer.

3 May 2011

HIV drugs may also combat parasitic diseases: Study

Scientists have discovered that drugs used to treat HIV may also one day become lifesaving drugs targeted at parasitic diseases such as leishmaniasis and malaria.

3 May 2011

Esperion reports positive results from ETC-1002 Phase 1 study in dyslipidemia

Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced the results from a Phase 1 study and four preclinical studies for ETC-1002 at the Arteriosclerosis, Thrombosis and Vascular Biology 2011 Scientific Sessions in Chicago.

3 May 2011

CTI deposits $10.6 million with U.S. Bank National Association, completes retirement of 7.5% convertible senior notes

Cell Therapeutics, Inc. today announced that it has deposited $10.6 million in cash as trust funds with U.S. Bank National Association, as the trustee of the outstanding 7.5% convertible senior notes, which is an amount sufficient to pay and discharge the entire amount due on the Notes, including accrued and unpaid interest.

2 May 2011

Invivo Therapeutics' Chief Science Officer selected as recipient of 2011 Apple Award

InVivo Therapeutics, a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries, today announced that Chief Science Officer Dr. Christopher Pritchard, Ph.D., has been selected as the 2011 recipient of the American Spinal Injury Association's prestigious Apple Award.

30 Apr 2011

Pearl's PT003 Phase 2b study results in COPD to be presented at ATS meeting

Pearl Therapeutics Inc. announced today that complete results from the Company's Phase 2b study of PT003 in patients with moderate-to-very severe COPD will be presented during a late-breaker poster session at the upcoming annual meeting of the American Thoracic Society.

30 Apr 2011

International Society of Nephrology honors BIDMC Co-director for immune tolerance research

Terry Strom, MD, Co-director of the Transplant Institute at Beth Israel Deaconess Medical Center and a leader in the field of immune tolerance research, was awarded the 2011 Alfred Newton Richards Award from the International Society of Nephrology during a program held earlier this month as part of the World Congress of Nephrology 2011 in Vancouver, Canada.

30 Apr 2011

Winner of MDEA Lifetime Achievement Award announced

UBM Canon's Medical Design Excellence Awards has announced the winner of the Medical Design Excellence Awards Lifetime Achievement Award. This award honors an individual whose contributions during a long career have had a demonstrable impact on technological, business, and cultural advancements in medical devices.

30 Apr 2011

IMPAKT 2011 conference to highlight new breast cancer studies

"The presentations at this year's IMPAKT reveal the innovative and diverse approaches that investigators are taking to identify the most encouraging new agents both before clinical evaluation and in early clinical studies. These range from ideas for novel clinical designs to the development of more sensitive and specific biomarkers and to data sharing that allows a more objective assessment of compounds prior to commitment of major clinical resources."

30 Apr 2011

Therapeutics News and Research

Promedior's PRM-151 clinical data in idiopathic pulmonary fibrosis to be presented at ATS 2011

The Miami Project, InVivo Therapeutics collaborate to develop novel spinal cord injury treatments

ZIOPHARM reports net loss of $39.0 million for first quarter 2011

Research experts to speak at brain tumor educational conference

TGen licenses ONCO-101 cancer drug to Syracuse

Selexys begins patient enrollment in SelG1 Phase I study for sickle cell disease

Durata receives positive EMA Scientific Advice on dalbavancin clinical development plan

Nile Therapeutics initiates cenderitide Phase I trial in heart failure

CTI to re-submit pixantrone NDA to FDA's Office of New Drugs for re-review

Astex earns GBP5.9 M milestone payment from GSK for fragment-based screening platform

JPO issues patent to Silence Therapeutics' RNAi technology

Guided Therapeutics launches LuViva Advanced Cervical Scan

HIV drugs may also combat parasitic diseases: Study

Esperion reports positive results from ETC-1002 Phase 1 study in dyslipidemia

CTI deposits $10.6 million with U.S. Bank National Association, completes retirement of 7.5% convertible senior notes

Invivo Therapeutics' Chief Science Officer selected as recipient of 2011 Apple Award

Pearl's PT003 Phase 2b study results in COPD to be presented at ATS meeting

International Society of Nephrology honors BIDMC Co-director for immune tolerance research

Winner of MDEA Lifetime Achievement Award announced

IMPAKT 2011 conference to highlight new breast cancer studies

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News